Advertisement

Topics

Valeant backlash continues: De Silva out at Endo

06:45 EDT 23 Sep 2016 | BioPharmaDive

Valeant's problems continue to make waves as another company tries to distance itself from the specialty pharma's bad business practices. 

Original Article: Valeant backlash continues: De Silva out at Endo

NEXT ARTICLE

More From BioPortfolio on "Valeant backlash continues: De Silva out at Endo"

Quick Search
Advertisement